Evidence map›Paper›PMID 35150061›Full record

ArticleJournal of cellular and molecular medicine2022

M2-phenotype tumour-associated macrophages upregulate the expression of prognostic predictors MMP14 and INHBA in pancreatic cancer.

Zhan-Wen Liang, Jie Yu, Dong-Mei Gu, Xiao-Meng Liu, Jin Liu, Meng-Yao Wu, Meng-Dan Xu, Meng Shen, Weiming Duan, Wei Li

Open access · goldAbstract read
In one paragraph

Article in Journal of cellular and molecular medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed
1.9field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed, 18 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Review
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 1 institution in 1 country.

Zhan-Wen LiangDepartment of Oncology, The First Affiliated Hospital of Soochow University, Suzhou, China.
Jie YuDepartment of Pathology, The First Affiliated Hospital of Soochow University, Suzhou, China.
Dong-Mei GuDepartment of Pathology, The First Affiliated Hospital of Soochow University, Suzhou, China.
Xiao-Meng LiuDepartment of Oncology, The First Affiliated Hospital of Soochow University, Suzhou, China.
Jin LiuDepartment of Oncology, The First Affiliated Hospital of Soochow University, Suzhou, China.
Meng-Yao WuDepartment of Oncology, The First Affiliated Hospital of Soochow University, Suzhou, China.
Meng-Dan XuDepartment of Oncology, The First Affiliated Hospital of Soochow University, Suzhou, China.
Meng ShenDepartment of Oncology, The First Affiliated Hospital of Soochow University, Suzhou, China.
Weiming DuanDepartment of Oncology, The First Affiliated Hospital of Soochow University, Suzhou, China.ORCID 0000-0003-3771-1212
Wei LiDepartment of Oncology, The First Affiliated Hospital of Soochow University, Suzhou, China.
Soochow University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Pancreatic cancer is one of the most lethal gastrointestinal tumours, the most common pathological type is pancreatic adenocarcinoma (PAAD). In recent year, immune imbalanced in tumour microenvironment has been shown to play an important role in the evolution of tumours progression, and the efficacy of immunotherapy has been gradually demonstrated in clinical practice. In this study, we propose to construct an immune-related prognostic risk model based on immune-related genes MMP14 and INHBA expression that can assess the prognosis of pancreatic cancer patients and identify potential therapeutic targets for pancreatic cancer, to provide new ideas for the treatment of pancreatic cancer. We also investigate the correlation between macrophage infiltration and MMP14 and INHBA expression. First, the gene expression data of pancreatic cancer and normal pancreatic tissue were obtained from The Cancer Genome Atlas Program (TCGA) and The Genotype-Tissue Expression public database (GTEx). The differentially expressed immune-related genes between pancreatic cancer samples and normal sample were screened by R software. Secondly, univariate Cox regression analysis were used to evaluate the relationship between immune-related genes and the prognosis of pancreatic cancer patients. A polygenic risk score model was constructed by Cox regression analysis. The prognostic nomogram was constructed, and its performance was evaluated comprehensively by internal calibration curve and C-index. Using the risk model, each patient gets a risk score, and was divided into high- or low- risk groups. The proportion of 22 types of immune cells infiltration in pancreatic cancer samples was inferred by CIBERSOFT algorithm, correlation analysis (Pearson method) was used to analyse the correlation between the immune-related genes and immunes cells. Then, we applied macrophage conditioned medium to culture pancreatic cancer cell line PANC1, detected the expression of MMP14 and INHBA by qRT-PCR and Western blot methods. Knock-down MMP14 and INHBA in PANC1 cells by transfected with shRNA lentiviruses. Detection of migration ability of pancreatic cells was done by trans-well cell migration assay. A subcutaneous xenograft tumour model of human pancreatic cancer in nude mice was constructed. In conclusion, an immune-related gene prognostic model was constructed, patients with high-risk scores have poorer survival status, M2-phenotype tumour-associated macrophages (TAMs) up-regulate two immune-related genes, MMP14 and INHBA, which were used to establish the prognostic model. Knock-down of MMP14 and INHBA inhibited invasion of pancreatic cancer.

Indexed as

AdenocarcinomaPancreatic NeoplasmsAnimalsBiomarkers, TumorGene Expression Regulation, NeoplasticHumansInhibin-beta SubunitsMatrix Metalloproteinase 14MiceMice, NudePhenotypePrognosisTumor-Associated MacrophagesTumor MicroenvironmentBiomarkers, Tumorinhibin beta A subunitInhibin-beta SubunitsMatrix Metalloproteinase 14MMP14 protein, human

Identifiers

PMID35150061
PMCPMC8899166
OpenAlexW4211058864

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.